• SEC Filings

Aethlon Medical, Inc. (NASDAQ:AEMD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01         Entry Into A Material Definitive Agreement.

Amendment No. 1 to Common Stock Sales Agreement with H.C. Wainwright

On August 6, 2019, Aethlon Medical, Inc. (“we”) executed Amendment No. 1 to our Common Stock Sales Agreement with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), effective as of August 5, 2019. The Common Stock Purchase Agreement was originally entered into by the parties on June 28, 2016 (as amended, the “Agreement”). The amendment provides that references in the Agreement to the Registration Statement shall refer to the registration statement on Form S-3 (File No. 333-231397), originally filed with the Securities and Exchange Commission on May 10, 2019, declared effective by the Securities and Exchange Commission on August 1, 2019.

Item 9.01         Financial Statements and Exhibits

AETHLON MEDICAL INC Exhibit
EX-10.1 2 aethlon_ex1001.htm AMENDMENT NO. 1 TO COMMON STOCK SALES AGREEMENT Exhibit 10.1   AMENDMENT NO. 1 TO common stock SALES AGREEMENT August 5,…
To view the full exhibit click here

About Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.